Sanofi

News

SparingVision raises €44.5m for retinitis pigmentosa gene th...

French biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare ocular disease.

News

Coronavirus vaccine: how pharma is picking up the pace

Sanofi preps trials of second COVID-19 shot, as Russia appro...

Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclini

News

Sanofi/Regeneron's Libtayo set for new skin cancer use

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings from a phase 2 trial in a hard to treat group of skin can

News

Roche's Actemra cuts chances of COVID-19 ventilator use in p...

Roche’s Actemra may help fight pandemic after all with phase 3 trial results showing it cut the chances of COVID-19 patients, mainly from higher risk minority ethnic backgrounds with pneumo

News

Health2Sync and Sanofi to digitally manage diabetes in Taiwa...

Taiwan-based digital health firm Health2Sync has partnered with Sanofi to help patients manage symptoms of diabetes.

News

AZ halts COVID-19 vaccine after safety scare, as UK faces 's...

It’s a bleak day in the fight against COVID-19, after the UK banned social gatherings of more than six people to contain growing numbers of new cases and the lead vaccine trial from AstraZe

SparingVision raises €44.5m for retinitis pigmentosa gene th...

Sanofi preps trials of second COVID-19 shot, as Russia appro...

Sanofi/Regeneron's Libtayo set for new skin cancer use

Roche's Actemra cuts chances of COVID-19 ventilator use in p...

Health2Sync and Sanofi to digitally manage diabetes in Taiwa...

AZ halts COVID-19 vaccine after safety scare, as UK faces 's...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Sanofi

Editor's Picks